Jefferies Downgrades Cerevel Therapeutics (CERE) to Hold
Tweet
Share
E-mailGet Alerts CERE Hot Sheet
Price: $44.96 --0%
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Jefferies analyst Michael J. Yee downgraded Cerevel Therapeutics (NASDAQ: CERE) from Buy to Hold with a price target of $45.00 (from $40.00).
For an analyst ratings summary and ratings history on Cerevel Therapeutics click here. For more ratings news on Cerevel Therapeutics click here.
Shares of Cerevel Therapeutics closed at $41.39 yesterday.
You May Also Be Interested In
- Morgan Stanley Downgrades Diamondback Energy (FANG) to Equalweight
- Morgan Stanley Upgrades Suncor Energy (SU) to Overweight
- CrowdStrike (CRWD) PT Adjusted $250 at Cantor Fitzgerald Post Stock Split
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
